Cowen and Company Reaffirms Outperform Rating for Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating restated by stock analysts at Cowen and Company in a research note issued to investors on Saturday. They presently have a $100.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $150.00. Cowen and Company’s price objective points to a potential upside of 191.80% from the stock’s current price.
A number of other brokerages have also weighed in on ALNY. JPMorgan Chase & Co. lowered shares of Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $83.00 to $51.00 in a report on Thursday. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 25th. FBR & Co reiterated an “outperform” rating and issued a $180.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 27th. Chardan Capital raised their target price on shares of Alnylam Pharmaceuticals from $77.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Jefferies Group cut their target price on shares of Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research note on Thursday. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Friday. The firm has a 50-day moving average of $70.69 and a 200 day moving average of $66.05. Alnylam Pharmaceuticals has a 1-year low of $33.16 and a 1-year high of $110.75. The firm’s market cap is $2.94 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/cowen-and-company-reaffirms-outperform-rating-for-alnylam-pharmaceuticals-inc-alny.html
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. Alnylam Pharmaceuticals’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the business earned ($0.85) EPS. On average, analysts predict that Alnylam Pharmaceuticals will post ($4.68) EPS for the current year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Aperio Group LLC increased its stake in Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 8,328 shares during the period. Pacad Investment Ltd. bought a new stake in Alnylam Pharmaceuticals during the first quarter worth approximately $490,000. BlackRock Inc. increased its stake in Alnylam Pharmaceuticals by 29.7% in the first quarter. BlackRock Inc. now owns 69,736 shares of the biopharmaceutical company’s stock worth $4,377,000 after buying an additional 15,965 shares during the period. BlackRock Group LTD increased its stake in Alnylam Pharmaceuticals by 21.9% in the first quarter. BlackRock Group LTD now owns 519,834 shares of the biopharmaceutical company’s stock worth $32,630,000 after buying an additional 93,450 shares during the period. Finally, BlackRock Fund Advisors increased its stake in Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock worth $115,395,000 after buying an additional 112,252 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.